Characteristics for All Evaluable Patients by Subpopulations Defined by Cutoffs for the 2 Methods
| Characteristics | All evaluable | ΔSUVmax > 66% | ΔSUVmax ≤ 66% | DS ≤ 3 | DS > 3 |
| No. of patients | 596 | 534 | 62 | 326 | 270 |
| Median age (y) | 62 (IQR, 51–70) | 62 (IQR, 51–70) | 62 (IQR, 50–69) | 62 (IQR, 52–70) | 61 (IQR, 50–70) |
| Age > 60 y (n) | 308 (51.8%) | 274 (51.4%) | 34 (54.8%) | 174 (53.5%) | 134 (49.6%) |
| Male sex (n) | 331 (55.5%) | 294 (55.1%) | 37 (59.7%) | 185 (56.7%) | 146 (54.1%) |
| ECOG performance status ≥ 2 (n) | 59 (9.9%) | 47 (8.8%) | 12 (19.4%) | 23 (7.1%) | 36 (13.3%) |
| Ann Arbor stage III or IV (n) | 349 (58.7%) | 304 (57.0%) | 45 (72.6%) | 173 (53.2%) | 176 (65.2%) |
| Extranodal sites > 1 (n) | 192 (32.3%) | 166 (31.1%) | 26 (41.9%) | 94 (28.9%) | 98 (36.3%) |
| Lactate dehydrogenase > ULN (n) | 329 (55.3%) | 289 (54.2%) | 40 (64.5%) | 151 (46.5%) | 178 (65.9%) |
| International Prognostic Index (n) | |||||
| Low risk | 219 (36.8%) | 205 (38.5%) | 14 (22.6%) | 140 (43.1%) | 79 (29.3%) |
| Low to intermediate risk | 155 (26.1%) | 137 (25.7%) | 18 (29.0%) | 83 (25.5%) | 72 (26.7%) |
| High to intermediate risk | 124 (20.8%) | 110 (20.6%) | 14 (22.6%) | 61 (18.8%) | 63 (23.3%) |
| High risk | 97 (16.3%) | 81 (15.2%) | 16 (25.8%) | 41 (12.6%) | 56 (20.7%) |
DS = Deauville score; IQR = interquartile range; ECOG = Eastern Cooperative Oncology Group; ULN = upper limit of normal.
Data on International Prognostic Index was not available for 1 patient with ΔSUVmax > 66% and DS > 3.